Researchers at MIT and elsewhere have developed Boltz-2, an open-source generative AI model that can help researchers find new medicines faster, reports Alex Knapp for Forbes. The tool “can not only predict the structure of proteins, it can also predict its binding affinity–that is, how well a potential drug is able to interact with that protein,” explains Knapp. “This is crucial in the early stages of developing a new medicine.”
Wall Street Journal reporter Dominique Mosbergen spotlights how Prof. James Collins and his lab have built their “own algorithms to trawl chemical databases, such as those of existing pharmaceutical drugs, for potential antibacterial compounds.” Collins’ His lab is “also experimenting with using generative AI to design completely new molecules that could kill bacteria,” writes Mosbergen.
Biogen will move its headquarters to a new facility at 75 Broadway in MIT’s Kendall Common development, reports Greg Ryan and Hannah Green for the Boston Business Journal. “The lease is one of the most significant life sciences real estate transactions in Greater Boston,” they write.
Biogen will move its headquarters to MIT’s Kendall Common development in 2028, reports Catherine Carlock and Jonathan Saltzman for The Boston Globe. “Biogen has been a foundational presence in the Massachusetts life science ecosystem for close to half a century,” says Governor Maura Healey. “We are thrilled to see them begin a new era in our state.”
Writing for Forbes, Senior Lecturer Guadalupe Hayes-Mota '08 MS '16, MBA '16 explores the challenges, opportunities and future of AI-driven drug development. “I see the opportunities for AI in drug development as vast and transformative,”
New Yorker reporter Dhruv Khullar spotlights how researchers from across MIT are using AI to advance drug development. Khullar highlights the MIT Jameel Clinic, the Broad Institute and various faculty members for their efforts in bridging the gap between AI and drug research. “With AI, we’re getting that much more efficient at finding molecules—and in some cases creating them,” says Prof. James Collins. “The cost of the search is going down. Now we really don’t have an excuse.”
Under the direction of CEO Noubar Afeyan PhD '87, a member of the MIT Corporation, Flagship Pioneering is using its resources to back life sciences companies, seeking to vertically integrate the processes of scientific discovery, reports Scott Kirsner for The Boston Globe. “Afeyan’s latest vision involves artificial intelligence and how it will change the way science and drug development are done,” he writes. “Afeyan says that AI could eventually become a tool that does much of the work of scientific discovery.”
Sonia Vallabh and Eric Minikel, senior group leaders from the Broad Institute have created a gene-editing tool to combat prion diseases, reports Karen Weintraub for USA Today. The approach “should also work against diseases such as Huntington's, Parkinson's, ALS and even Alzheimer's, which result from the accumulation of toxic proteins,” Weintraub writes.
ShareAmerica reporter Lauren Monsen spotlights Prof. Dina Katabi for her work in advancing medicine with artificial intelligence. “Katabi develops AI tools to monitor patients’ breathing patterns, hear rate, sleep quality, and movements,” writes Monsen. “This data informs treatment for patients with diseases such as Parkinson’s, Alzheimer’s, Crohn’s, and ALS (amyotrophic lateral sclerosis), as well as Rett syndrome, a rare neurological disorder.”
Senior Lecturer Guadalupe Hayes-Mota writes for Forbes about the ways AI is reshaping drug development. “In the next three years, we can anticipate a more streamlined, efficient and cost-effective drug development process, ultimately leading to faster access to life-saving drugs for patients worldwide,” Hayes-Mota writes. “This is not just an evolution; it is a revolution in healthcare powered by the intelligence of machines.”
Landmark Bio, a cell and gene therapy manufacturing company co-founded by MIT and a number of other institutions, is focused on accelerating access to innovative therapies for patients, reports Rowan Walrath for Boston Business Journal. "Landmark's new facility includes laboratory space for research and early-stage drug development, as well as analytics tools,” writes Walrath.
MIT and a number of other local institutions have launched Landmark Bio, a cell and gene therapy manufacturing firm aimed at helping small startups develop experimental therapies that are reliable, consistent, and large enough to be used in clinical trials, reports Ryan Cross for The Boston Globe.
Washington Post reporter Pranshu Verma writes about how Prof. Dina Katabi and her colleagues developed a new AI tool that could be used to help detect early signs of Parkinson’s by analyzing a patient’s breathing patterns. For diseases like Parkinson’s “one of the biggest challenges is that we need to get to [it] very early on, before the damage has mostly happened in the brain,” said Katabi. “So being able to detect Parkinson’s early is essential.”
Forbes contributor Jennifer Kite-Powell spotlights how MIT researchers created a new AI system that analyzes radio waves bouncing off a person while they sleep to monitor breathing patterns and help identify Parkinson’s disease. “The device can also measure how bad the disease has become and could be used to track Parkinson's progression over time,” writes Kite-Powell.
A new tool for diagnosing Parkinson’s disease developed by MIT researchers uses an AI system to monitor a person’s breathing patterns during sleep, reports Hiawatha Bray for The Boston Globe. “The system is capable of detecting the chest movements of a sleeping person, even if they’re under a blanket or lying on their side,” writes Bray. “It uses software to filter out all other extraneous information, until only the breathing data remains. Using it for just one night provides enough data for a diagnosis.”